Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
41 hedge funds and large institutions have $180M invested in Evelo Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 11 closing their positions.
590% more call options, than puts
Call options by funds: $207K | Put options by funds: $30K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $180M → $180M (-$383K)
11% less funds holding
Funds holding: 46 → 41 (-5)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.26M |
| 2 |
BlackRock
New York
|
+$673K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$548K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$241K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$52.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$826K |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$716K |
| 3 |
E
Ergoteles
New York
|
-$633K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$621K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$423K |
EVLO Hedge Fund Activity: Q3 2022 in Review
41 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2022, worth a combined $180M — down 0.21% from $180M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of EVLO and 6 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $4.26M. The largest seller was CVI Holdings, cutting an estimated $826K.
- 41 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2022, down from 46 in Q2 2022.
- Funds reported $180M of Evelo Biosciences, Inc. Common Stock stock for Q3 2022, down 0.21% quarter-over-quarter.
- 6 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2022 and 11 closed out, a net change of -5 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $4.26M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2022 was CVI Holdings, an estimated $826K sold.
Based on aggregated 13F filings for Q3 2022.